Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG
Titel:
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG
Auteur:
Schadendorf, D. Ugurel, S. Schuler-Thurner, B. Nestle, F.O. Enk, A. Bröcker, E.-B. Grabbe, S. Rittgen, W. Edler, L. Sucker, A. Zimpfer-Rechner, C. Berger, T. Kamarashev, J. Burg, G. Jonuleit, H. Tüttenberg, A. Becker, J.C. Keikavoussi, P. Kämpgen, E. Schuler, G.